Thursday, June 5, 2014 Hyatt Regency San Francisco
|
|
- Brice Bruce
- 8 years ago
- Views:
Transcription
1 Thursday, June 5, 2014 Hyatt Regency San Francisco Regenerative Medicine and Cellular Therapy All education session events will take place in the Grand Ballroom. 8:00am 8:10am Introduction Joanne Kurtzberg, MD, Duke University Medical Center 8:10am 9:50am Session IA: How Are Stem Cells Marching to the Clinic? Moderator Andrew Balber, PhD, Duke University The View From Academia Mahendra Rao, MD, PhD, National Institute of Health The View From Industry Edward Field, MBA, Cytomedix, Inc. Advancing Stem Cell Science Towards Therapies for Patients: CIRM s Experience and Future Directions Ellen Feigal, MD, CIRM 9:50am 10:10am 10:10am 12:30pm Session IB: Cellular Therapies for Neurological Diseases, Treatments Near or In the Clinic Today Moderator TBD Therapeutic Use of Oligodendrocyte Progenitor Cells for Brain Remyelination Martha Windrem, MD, University of Rochester Autologous Cord Blood Shows Promise in the Treatment of HIE Michael Cotton, MD, Duke University Medical Center Utilization of Multiple Autologous Cord Blood Infusions to Treat Children With Brain Injury Joanne Kurtzberg, MD, Duke University Medical Center A Randomized Trial of Autologous Bone Marrow vs. Cord Blood in Children with CP Charles S. Cox, Jr., MD, University of Texas Houston Medical School Cord Blood to Treat CP in Children: What are the Pathways to Allogeneic Cell Therapies? Joanne Kurtzberg, MD, Duke University Medical Center 12:30pm 1:30pm Lunch Pacific Concourse
2 1:30pm 3:30pm Session IIA: Derivative Products from CORD Blood and Placental Tissue Moderator - Jennifer Willert, MD, Stanford University Development of More Than Minimally Manipulated Cord Blood Products: Pathways for Academic Development Colleen Delaney, MD, Fred Hutchinson Cancer Research Center The Potential for Cord Blood Derived MSC in RM: Manufacturing and Clinical Issues Morey Kraus, PhD, ViaCord Preclinical Evidence That Cord Blood Derived Endothelial Colony Forming Cells Display Potential as Vasculo-Reparative Agents Mervin C. Yoder, MD, University of Indiana New Horizons for the Ex Vivo Modulation of Cord Blood Daniel Shoemaker, PhD, Fate Therapeutics 3:30pm 3:50pm 3:50pm 5:10pm Session IIB: Challenges and Opportunities for Resourcing, Financing and Regulating Development and Clinical Use of Cord Blood Products in Regenerative Medicine Moderator - Joanne Kurtzberg, MD, Duke University Medical Center Current Costs of Blood Transplants: Impact of Licensure on Cord Blood Transplants, Implications for the Use of CB in RM Michael Boo, JD, NMDP Regulatory Challenges to Bringing Cord Blood Derived Products to the Clinic Mercy Quagraine, PhD, FDA Innovative Financing and Insurance of Cord Blood Banking for Better Future Use of Cord Blood Units in Regenerative Medicine Arie Giniger, PhD, Irsael 5:10 pm 5:30pm Discussion & Closing Comments 5:30 pm 7:30pm Welcome and Abstract Poster Reception, Grand Ballroom Foyer and Market Street Foyer
3 Friday, June 6, 2014 CLINICAL TRANSPLANTATION AND CORD BLOOD BANKING 8:00am 9:30am SESSIONS IIIA: The Necessity and Urgency of Encouraging Appropriate Utilization of Cord Blood Transplantation Moderators Joseph Alvarnas, MD, City of Hope & Vanderson Rocha, MD, PhD, Eurocord and Oxford University 8:00am 8:30am The Problem of Absent or Late Referrals by Hematologists and Efforts Toward Improvement Joseph Alvarnas, MD, City of Hope 8:30am 8:50am Expanding the Indications of Cord Blood Transplantation: HCT for Patients with Hematologic Malignancies in the Sixth to Eighth Decades of Life Amanda Olson, MD, MD Anderson Cancer Center 8:50am 9:10am Expanding the Indications for Cord Blood Transplantation: New Cohorts Who Might Likely Benefit Daniel Weisdorf, MD, University of Minnesota 9:10am 9:30am Unrelated Cord Blood Transplantation has Outcomes Comparable to Similar Patient Groups Treated with Matched Unrelated Donor Transplants. Annalisa Ruggeri, MD, Eurocord International Registry 9:30am 9:50am 9:50am 12:00pm Session IIIB: The Necessity and Urgency of Encouraging Appropriate Utilization of Cord Blood Transplantation (cont) Moderators Joseph Alvarnas, MD, City of Hope & Vanderson Rocha, MD, PhD, Eurocord and Oxford University 9:50am 10:20am Comparative Outcomes After RIC UCBT vs. RIC 8/8 PB in Adults with Lymphoid Malignancies Vanderson Rocha, MD, PhD, Eurocord and Oxford University 10:20am 10:40am Transplantation for All Patients Including Those of Racial and Ethnical Minorities: Improved Allograft Access with Enlarging CB Inventory Parastoo B. Dahi, MD, Memorial Sloan-Kettering Cancer Center 10:40am 11:00am Chronic GVHD Burden is Lower Following Adult Cord Blood Versus MURD Transplant Jonathan Gutman, MD, University of Colorado
4 11:00am 11:20 am Alternative Donors Extend Transplantation for Patients With Lymphoma Who Lack an HLA Matched Donor Veronika Bachnova, MD, University of Minnesota 11:20am 12:00pm Discussion of SESSIONS IIIA and IIIB 12:00pm-1:00pm Lunch Pacific Concourse 1:00pm 3:00pm Session IV: What is the Optimal Means of Providing Adequate Cell Does in Cord Blood Transplantation? Discussion and Debate Moderator Claudio Brunstein, MD, University of Minnesota 1:00pm 1:20pm Double Cord Blood HCT Juilet Barker, MBBS, FRACP, Memorial Sloan-Kettering Cancer Center 1:20pm 1:40pm Cell Expansion Colleen Delaney, MD, Fred Hutchinson Cancer Research Center 1:40pm 2:00pm Dual Haplo/CB HCTs Koen Van Besien, PhD, NYP-Weill Cornell College of Medicine 2:00pm 2:20pm Haploidentical Hematopoietic Cell Transplantation. Richard Champlin, MD, MD Anderson Cancer Center 2:20pm 3:00 pm Discussion and Debate 3:00pm 3:20pm 3:20pm 5:00pm Session IV: The Selection of Optimal Donors for CB HCT Moderators Mary Eapen, MD, Medical College of Wisconsin & Sarah Cooley, MD, University of Minnesota 3:20pm 3:40pm Toward Eliminating HLA Class I Expression to Generate Universal Cells From Allogeneic Donors Hiroki Troikai, MD, MD Anderson Cancer Center
5 3:40pm 4:00pm The Significance of Allele-Level HLA-Matching after Myeloablative Single CB Transplantation for Hemotologic Malginancy Mary Eapen, MD, Medical College of Wisconsin 4:00pm 4:20pm Killer Cell Immunoblobulin-like receptor (KIR) Typing to Select Donors with Potential Natural Killer (NK) Alloreactivity Sarah Cooley, MD, University of Minnesota 4:20pm 4:40pm Outcomes of Patients with Hemoglobinopathies Given Either CB or BM HCT from an HLA-identical Sibling Mark Walters, MD, Children s Hospital and Research Center of Oakland 4:40pm 5:00pm 5:30pm 6:30pm Discussion Cytolon Industry Workshop, Bayview B Room 6:30 pm 8:30 pm MNX Reception, Atrium
6 Saturday, June 7, 2014 Cord Blood Banking & Clinical Advancements 8:00am 9:40am Session VI: New Findings Regarding GVHD, Minimal Residual Disease and the Use of ATG Moderators Doris Ponce, MD, Memorial Sloan-Kettering Cancer Center; Michael Pulsipher, MD, University of Utah 8:00am 8:30am The Prevention and Management of GVHD Doris Ponce, MD, Memorial Sloan-Kettering Cancer Center 830am 8:45am The Role of Regulatory: T cells in Preventing GVHD Claudio Brunstein, MD, University of Minnesota 8:45am 9:00am Striking Predictive Power for Relapse and Decreased Survival with Detectable Minimal Residual Disease Michael Pulsipher, MD, University of Utah 9:00am 9:15am Quantitative Assessment of T cell Repertoire Recovery After Umbilical Cord Blood Transplantation Using Next Generation Sequencing Miguel-Angel Perales, MD, Memorial Sloan-Kettering Cancer Center 9:15am 9:30am Facilitating Engraftment in Patients at High Risk for Graft Rejection Following Reduced Intensity Conditioning: An Alternative to ATG Rachel Salit, MD, Fred Hutchinson Cancer Research Center 9:30am 9:40am Discussant: Vanderson Rocha, MD, PhD 9:40am 10:00am 10:00am 12:00pm Session VII: Means to Enhance Engraftment of Cord Blood Cells Moderators - Elizabeth Shpall, MD, MD Anderson Cancer Center & Mitchell Horwitz, MD, Duke University Medical Center 10:00am 10:20am Fucosylation with Fucosyltransferase VI or Fucosyltransferase VII improves Cord Blood Engraftment Elizabeth Shpall, MD, MD Anderson Cancer Center
7 10:20am 10:40am Umbilical Cord Blood Stem Cells Cultured in the Presence of Nicotinamide (NiCord ) Provide Long Term Multi-lineage Engraftment Mitchell Horwitz, MD, Duke University Medical Center 10:40am 11:00am Update of Modified Dosing for Inhibition of DPP4 by Sitagliptin to Enhance Single Cord Blood Transplantation in Adult Patients With High Risk Leukemia and Lymphoma Sherif S. Farag, MD, University of Indiana 11:00am 11:20am PGE 2 -Modulated Umbilical Cord Transplantation Corey Cutler, MD, Dana-Farber Cancer Institute 11:20am 11:40am Determinants of Engraftment After Double-unit Cord Blood Transplantation: The Importance of CD34+ Cell Dose and Cord Blood Bank Practices Duncan Purtill, MBBS, FRACP, FRCPA, Memorial Sloan-Kettering Cancer Center 11:40am 12:00pm 12:00pm-1:00pm Discussion Lunch Pacific Concourse 1:00pm 3:00pm Session VIII: New Aspects of Cord Blood Cell Transplantation Moderators - Jiangiang Li, PhD, Fred Hutchinson Cancer Research Center & Michael Verneris, MD, University of Minnesota 1:00pm 1:15pm The Best Abstract Submission: Optimizing the Outcomes of Unrelated HLA-Mismatched Cord Blood Transplantation: Predicted Indirectly Recognizable HLA Epitopes - A Possible Novel Donor Selection Tool for Better Disease Control and Reducing the Transplant-Related Toxicity. Kirsten A.Thus, MD, --- University Medical Center, Utrecht 1:15pm 1:40pm Antigen Presenting Cell-mediated Expansion of Human Umbilical Cord Blood Yields Long-scale Expansion of Natural Killer Cells with Anti-myeloma Activity Nina Shah, MD, MD Anderson Cancer Center 1:40pm 2:00pm Early NK Cell Proliferation after CB Transplantation is Associated with Superior Disease-Free Survival Due to Reduced Leukemia Relapse Michael Verneris, MD, University of Minnesota
8 2:00pm 2:20pm Clinical Application and Therapeutic Effect of Fetal Mesenchymal Stem Cells in Prenatal Transplantation Steven Shaw, MD, MSc, PhD, Chang Gung Memorial Hospital 2:20pm 2:40pm Three Kingdoms Saga: Exploring the Mechanism of Graft versus Graft Interactions and Its Influence on Outcomes in Cord Blood Transplant Recipients Jiangiang Li, PhD, Fred Hutchinson Cancer Research Center 2:40pm 3:00pm Experience of Pediatric Stem Cell Transplants in AIIMS, Delhi, India Sameer Bakhshi, MD, All India Institute of Medical Sciences 3:00pm 3:20pm 3:20pm 5:00pm Session IX: Cord Blood Banking Including Cost Considerations Moderators Michael Boo, JD, NMDP & Joanne Kurtzberg, MD, Duke University Medical Center 3:20pm 3:25pm Impact of Umbilical Cord Blood Processing on Transplant Outcomes Karen Ballen, MD, Massachusetts General Hospital 3:35pm 4:15pm Costs: The Perspective of a Transplant Physician Elizabeth Shpall, MD, MD Anderson Cancer Center 3:45pm 3:55pm Costs; The Perspective of a Cord Blood Banker Joanne Kurtzberg, MD, Duke University Medical University 3:55pm 4:05pm Cord Blood Banking: Overview of Relative Costs of Cell Source Michael Boo, JD, NMDP 4:05pm 4:15pm Discussion 4:15pm 4:30pm Navigating Consent Issues in the Collection of Licensed Units: How Should Potential Research Uses be Addressed in the Consent at Collection? Roberta King, MPH, NMDP 4:30pm 4:45pm The Role of Post-Thaw Potency Testing in the Selection of Cord Blood Units Donna Regan, MT(ASCP)SBB, St. Louis Cord Blood Bank 4:45pm 5:00pm Discussion
9 Adjournment Until 2015
Program Co-Chairmen: Dr. John Wagner, University of Minnesota Dr. Richard Champlin, M.D. Anderson Cancer Center
(last updated May 13, 2004) This is an activity offered by CBBS, a CMA accredited provider. Physicians attending this course may report up to 13.25 hours of Category 1 credits toward the California Medical
More information10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program. Thursday, June 7
10 th Annual International Cord Blood Transplantation Symposium June 7-9, 2012 Preliminary Scientific Program Thursday, June 7 7:00 8:00 AM Breakfast in Exhibit Hall Session IA 8:00 10:00 AM Advances in
More informationFetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant. Recipients
Fetal Maternal Immunity and Antileukemia Activity in Cord Blood Transplant Recipients Filippo Milano, 1 J. Lee Nelson, 1, 2 Colleen Delaney 1,3 1 Clinical Research Division, Fred Hutchinson Cancer Research
More informationPr Eliane Gluckman, MD, FRCP, Disclosure of Interest: Nothing to Disclose
Pr Eliane Gluckman, MD, FRCP, Hospital Saint Louis, University Paris- Diderot, France Should Haplo-identical transplantation be preferred to cord blood in patients without a matched donor? Disclosure of
More informationBeyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit. Karen Ballen, MD Massachusetts General Hospital June, 2012
Beyond Cell Dose: Selection of the Optimal Umbilical Cord Blood Unit Karen Ballen, MD Massachusetts General Hospital June, 2012 OUTLINE Cell Dose HLA Typing HLA C and KIR HLA Antibodies ABO and Racial/Ethnic
More informationSelection of the Optimal Umbilical Cord Blood Unit
Karen Ballen, MD Selection of the Optimal Umbilical Cord Blood Unit Massachusetts General Hospital September, 2013 OUTLINE Cell Dose HLA Match Allele Level HLA C KIR Directional Mismatch NIMA HLA Antibodies
More informationUMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE
UMBILICAL CORD BLOOD TRANSPLANTATION: KFSH EXPERIENCE HIND AL HUMAIDAN, MD,FRCPA Director, Blood Bank (Donor & Transfusion Services) and Stem Cell Cord Blood Bank Consultant Hematopathologist INTRODUCTION
More informationUmbilical Cord Blood Transplantation
Umbilical Cord Blood Transplantation V Rocha MD, PhD Hopital Saint Louis, Paris University 7 CIBMTR Milwaukee Umbilical Cord blood transplantation Background History Clinical results in children and adults
More informationEUROCORD. in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases
! 21%! EUROCORD 6756 cord blood transplantations performed from 1988 to March 2010 in 49 countries and 484 transplant centres* 264 EBMT 4847 (73%) cases 220 Non-EBMT 1797 (27%) cases * missing center
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationStatement of Joanne Kurtzberg, M.D.
Statement of Joanne Kurtzberg, M.D. President of the Cord Blood Association Jerome Harris Distinguished Professor of Pediatrics and Pathology Chief Scientific Officer and Medical Director, Robertson Clinical
More informationCHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION
CHAPTER 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION Chapter 1 BACKGROUND AND CORD BLOOD BANK (CBB) ORGANIZATION 1.1 OVERVIEW OF THE CORD BLOOD TRANSPLANTATION STUDY Bone marrow transplantation
More informationThe donor search: the best donor or cord blood unit
The donor search: the best donor or cord blood unit Dr Bronwen Shaw Consultant in haematopoietic cell transplantation Royal Marsden Hospital /Anthony Nolan Overview Where do we find donors/units for transplantation
More informationSelecting an appropriately matched donor for hematopoietic
Transplant Outcomes in Acute Leukemia (I) Mary Eapen a and John E. Wagner b Umbilical cord blood (UCB) has gradually emerged over the last decade as an alternative source of hematopoietic cells for transplantation
More informationCord Blood Market Trends, circa 2014
GENReports: Market & Tech Analysis Cord Blood Market Trends, circa 2014 > Enal Razvi, Ph.D. Managing Director Select Biosciences, Inc. enal@selectbio.us Topic Introduction and Scope The focus of this GEN
More informationCord Blood Transplant. E. Gluckman Eurocord ESH-EBMT training course Vienna 2014
Cord Blood Transplant E. Gluckman Eurocord ESH-EBMT training course Vienna 2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationInternational NetCord Foundation Executive Committee Conference Call Minutes May 23, 2007
International NetCord Foundation Executive Committee Conference Call Minutes Committee Members: Board Members: Staff: President Joan Garcia and Drs. Yves Beguin and Elizabeth Shpall Drs. Cristina Navarrete
More informationCorporate Medical Policy Cord Blood as a Source of Stem Cells
Corporate Medical Policy Cord Blood as a Source of Stem Cells File Name: Origination: Last CAP Review: Next CAP Review: Last Review cord_blood_as_a_source_of_stem_cells 2/2001 3/2015 3/2016 3/2015 Description
More informationNavelstrengbloed tegen kanker
Navelstrengbloed tegen kanker THERAPIEDAG 2008: "Zorgtrajecten in kanker" Zaterdag 27 september 2008 Gasthuisberg, Leuven. Hélène Schoemans, MD KUL, Stem Cell Institute Leuven Cord blood Collection and
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2015 Origination: 12/2001 Next Review: 12/2016 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationCord Blood: Research Progress and Future Promise
Cord Blood: Research Progress and Future Promise By Al Staropoli, AABB Contributing Writer Sue Fister found out she had leukemia when she was 50 years old. Doctors suggested a bone marrow transplant as
More informationUmbilical Cord Blood Stem Cells Current Status & Future Potential
Umbilical Cord Blood Stem Cells Current Status & Future Potential Natasha Ali Assistant Professor Haematology Department of Pathology & Laboratory Medicine/Oncology The Aga Khan University Email: natasha.ali@aku.edu
More informationCord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape
GENReports: Market & Tech Analysis Cord Blood for Cellular Therapy: A Snapshot of this Evolving Market Landscape > Enal Razvi, Ph.D. Biotechnology Analyst, Managing Director SELECTBIO US enal@selectbio.us
More informationHow To Transplant Cord Blood
MP 7.01.38 Placental/Umbilical Cord Blood as a Source of Stem Cells Medical Policy Section Surgery Issue 12:2013 Original Policy Date 12:2013 Last Review Status/Date Reviewed with literature search/12:2013
More informationHematopoietic Stem Cell Transplantation. Imad A. Tabbara, M.D. Professor of Medicine
Hematopoietic Stem Cell Transplantation Imad A. Tabbara, M.D. Professor of Medicine Hematopoietic Stem Cells Harvested from blood, bone marrow, umbilical cord blood Positive selection of CD34 (+) cells
More informationIn contrast to the very high transplant-related
Cord Blood: an Alternative Stem Cell Source or a New Standard? Juliet N. BARKER Memorial Sloan-Kettering Cancer Center, NY, ABD In contrast to the very high transplant-related mortality (TRM) associated
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? Federica Giannotti, MD Eurocord-Hôpital Saint Louis, Paris Background Hematopoietic stem cell transplantation (HSCT) is
More informationCord Blood: that other stem cell source. Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program
Cord Blood: that other stem cell source Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program CBMTG April 2012 The problem: In order to perform a BMT from one person to another one needs
More informationSaving your baby s s cord blood: Is this good insurance?
Saving your baby s s cord blood: Is this good insurance? 32 th SEMINAR ON PERINATAL MEDICINE CONTROVERSIES IN PERINATAL MEDICINE: EVIDENCE FOR CURRENT PRACTICE Sante Fe, New Mexico Mervin C. Yoder, MD
More informationProcessing & Utilization of Cord Blood for Transplant
Processing & Utilization of Cord Blood for Transplant 2010-Jan Jan-15 Nicole L. Prokopishyn, PhD HPC Processing Laboratory Director Calgary Laboratory Services Overview Cord Blood Processing Pre-Freeze
More informationDo you have anything to add? If so, I d love to hear from you! Jessica Robinson Conference Manager Life Sciences @jessbiopharma
1 Who is the most influential figure in cord blood around the world? What is the biggest challenge to overcome in the use of cord blood as a source of stem cells? We asked 10 leading experts in the cord
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2014 Origination: 12/2001 Next Review: 12/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationSection: Transplant Last Reviewed Date: January 2015. Policy No: 45.16 Effective Date: April 1, 2015
Medical Policy Manual Topic: Placental and Umbilical Cord Blood as a Source of Stem Cells Date of Origin: December 2009 Section: Transplant Last Reviewed Date: January 2015 Policy No: 45.16 Effective Date:
More informationStem cells from Cord Blood: Myths, reality and potential. Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute
Stem cells from Cord Blood: Myths, reality and potential Elisabeth Semple, PhD Scientific Director Cells for Life Cord Blood Institute Learning objectives Understand the current usage of stem cells from
More informationTransplantation of cord blood stem cells from related or unrelated donors is considered investigational in all other situations.
MEDICAL POLICY POLICY RELATED POLICIES POLICY GUIDELINES DESCRIPTION SCOPE BENEFIT APPLICATION RATIONALE REFERENCES CODING APPENDIX HISTORY Placental and Umbilical Cord Blood as a Source of Stem Cells
More informationA Cure for Sickle Cell Anemia and Thalassemia
IV Simpósio Internacional de Hemoglobinopatias A Cure for Sickle Cell Anemia and Thalassemia Bertram Lubin, MD and Mark Walters, MD 4 September 2007 Topics to be covered Cord blood: Importance and biology
More informationCord Blood Stem Cell Transplantation
LEUKEMIA LYMPHOMA MYELOMA FACTS Cord Blood Stem Cell Transplantation No. 2 in a series providing the latest information on blood cancers Highlights Umbilical cord blood, like bone marrow and peripheral
More informationCord Blood Transplant Past and Future. E. Gluckman Eurocord ISCT Paris 24/04/2014
Cord Blood Transplant Past and Future E. Gluckman Eurocord ISCT Paris 24/04/2014 Background Since 1988, umbilical cord blood (CB) has been successfully used to treat children and adults needing stem cell
More informationSo, get comfortable and enjoy finding out what the greatest achievements and challenges are facing the industry today.
1 Who is the most influential figure in cord blood around the world? What do you think has been the biggest achievement within the cord blood sector? Which is the most important development in cord blood
More informationPlacental and Umbilical Cord Blood as a Source of Stem Cells
Placental and Umbilical Cord Blood as a Source of Stem Cells Policy Number: 7.01.50 Last Review: 12/2013 Origination: 12/2001 Next Review: 12/2014 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationNatasha Kekre, 1 Jennifer Philippe, 2 Ranjeeta Mallick, 3 Susan Smith, 2 and David Allan 1,2,4. 1. Introduction
Hindawi Publishing Corporation Stem Cells International Volume 2013, Article ID 124834, 6 pages http://dx.doi.org/10.1155/2013/124834 Research Article Modelling Improvements in Cell Yield of Banked Umbilical
More informationDisclosures. I have no disclosures.
Not Your Own Marrow Jenni Krajewski, MD Clinical Assistant Professor, Rutgers New Jersey Medical School Attending Physician, Pediatric Blood and Marrow Transplantation The Institute for Pediatric Cancer
More information4. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement on the Utility of Autologous or Family Cord Blood Unit Storage The WMDA Board adopted this policy on 25 th of May 2006. Policy updated _April 2011 The Cord Blood Working Group and
More informationPreparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between
Preparation of cord blood for infusion: bedside thaw, dilute and wash, or somewhere in between Donna Wall, MD Director, Manitoba Blood and Marrow Transplant Program ISCT 2012 Disclosures: none The problem:
More informationSTEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE
STEM CELLS FROM THE UMBLICAL CORD BLOOD AND UMBLICAL CORD TISSUE What are Stem Cells? Stem cells are the basic building blocks of all the cells, tissues and organs in the human body. The role of the stem
More informationPros and Cons of Stem Cell Sources and their availability in Africa. Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa
Pros and Cons of Stem Cell Sources and their availability in Africa Dr Jaimendra Singh Inkosi Albert Luthuli Central Hospital Durban, South Africa Introduction The ability to perform a haematopoietic stem
More informationThe Power & Potential of Cord Blood
The Power & Potential of Cord Blood Donna Regan, MT(ASCP)SBB, Director St. Louis Cord Blood Bank & Cellular Therapy Laboratory SSM Cardinal Glennon Children s Medical Center April 30, 2014 Objectives Since
More informationCorporate Medical Policy
Corporate Medical Policy Hematopoietic Stem-Cell Transplantation for CLL and SLL File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_cll_and_sll
More informationName of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells
Name of Policy: Placental/Umbilical Cord Blood as a Source of Stem Cells Policy #: 439 Latest Review Date: September 2014 Category: Medical Policy Grade: A Background/Definitions: As a general rule, benefits
More informationAdvances in HSC Transplantation for Myelodysplasia: Cord Blood Transplantation & RIC
Advances in HSC Transplantation for Myelodysplasia: Cord Blood Transplantation & RIC -7-6 -5-4 -3-2 -1 0 30 100 CSA/ MMF Juliet N. Barker, MBBS (Hons), FRACP Associate Attending Director Cord Blood Transplant
More informationHow to select a donor and product for allogeneic HCT
How to select a donor and product for allogeneic HCT Dr Bronwen Shaw 10 February 2015 Overview Who (and where) are the donors What factors determine how we choose between them Acquisition Clinical Donor
More information5. All cord blood banks should be subject to the same standards, regulations and accreditation requirements.
WMDA Policy Statement for the Utility of Autologous or Family Cord Blood Unit Storage (This policy statement has been approved and adopted by the WMDA board on the 25 th of May 2006) The Cord Blood Registries
More informationCigna Medical Coverage Policy
Cigna Medical Coverage Policy Subject Umbilical Cord Blood Banking Table of Contents Coverage Policy... 1 General Background... 1 Coding/Billing Information... 3 References... 4 Effective Date... 6/15/2014
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): 4/1/2011 Most Recent Review Date (Revised): 3/24/2015 Effective Date: 6/1/2015 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER
More informationDouble cord blood transplantation
DCTH - 2 2013-113-121 REVIEW Double cord blood transplantation R. Angarano, I. Donnini, B. Bartolozzi, A. Bosi Ematologia, Azienda Ospedaliera Universitaria Careggi, Università di Firenze, Italy SUMMARY
More informationHow To Support Umbilical Cord Blood Stem Cell Research
Cauley O. Gieb Advanced Health Law HLP Article Umbilical Cord Blood Stem Cell Research: The Proof is in the Cord Today advances in science seem to gain the most recognition and support when the subject
More informationCIGNA HEALTHCARE COVERAGE POSITION
CIGNA HEALTHCARE COVERAGE POSITION Subject Umbilical Cord Blood Banking Table of Contents Coverage Position... 1 General Background... 1 Coding/Billing Information... 3 References... 3 Revised Date...
More informationAutomated Cord Blood Processing:
TM Automated Cord Blood Processing: A Follow-up to the Pilar Solves Study Comparing the AXP vs the Sepax Cord Blood Processing Systems CHRISTY KIM, PETRA CRAVENS, MINDY WILKE-DOUGLAS AND MITCHEL SIVILOTTI
More informationCord Cor Blood Banking Scott N. Furlan, MD Ellen S. Plummer, Plummer MD
Cord Blood Banking Scott N. Furlan, MD Ellen S.Plummer, MD Overview Background Biology of Stem Cell Transplant Opportunities i at Parkland Logistics of Banking Potential Barriers Indications for HCT Cancer
More informationCORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE
CORD BLOOD TRANSPLANTATION: PAST, PRESENT AND FUTURE Dennis M. Todd, Ph.D. The New Jersey Cord Blood Bank a Division of Bergen Community Regional Blood Center Montvale, NJ Hematopoietic Stem Cell Transplantation
More informationInternational NetCord Foundation Executive Committee Conference Call Minutes September 10, 2014
International NetCord Foundation Executive Committee Conference Call Minutes September 10, 2014 Committee Members: Staff: President Etienne Baudoux and Drs. Gesine Koegler, Joanne Kurtzberg and Alexander
More informationDeterminants of Engraftment after Double-Unit Cord Blood Transplantation
In: Broxmeyer HE, ed. Cord Blood: Biology, Transplantation, Banking, and Regulation Bethesda, MD: AABB Press, 2011 26 Determinants of Engraftment after Double-Unit Cord Blood Transplantation Doris M. Ponce,
More informationThe Power & Potential of Cord Blood
The Power & Potential of Cord Blood Donna Regan, MT(ASCP)SBB, Director St. Louis Cord Blood Bank & Cellular Therapy Laboratory SSM Cardinal Glennon Children s Medical Center September 18, 2013 Objectives
More informationUmbilical cord blood transplantation
Review article http://dx.doi.org/10.3345/kjp.2012.55.7.219 Korean J Pediatr 2012;55(7):219-223 eissn 1738-1061 pissn 2092-7258 Umbilical cord blood transplantation Hong Hoe Koo, MD 1, Hyo Seop Ahn, MD
More informationHow To Buy A Black/White Cord Blood Stem Cell
AD AWARD NUMBER: W81XWH-05-1-0266 TITLE: Cord Blood Stem Cell Procurement in Minority Donors PRINCIPAL INVESTIGATOR: Voravit Ratanatharathorn, M.D. CONTRACTING ORGANIZATION: Wayne State University Detroit,
More informationCancer: A Comparison of Cord Blood and Bone-marrow transplantation
UMBILICAL-CORD BLOOD TRANSPLANTATION FOR THE TREATMENT OF CANCER Juliet N. Barker* and John E. Wagner Haematopoietic stem-cell transplantation is used to treat many haematological cancers, but is limited
More informationBone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? E. Gluckman WBMT meeting Cape Town November 14-16, 2014
Bone Marrow, Peripheral Blood Stem Cells or Umbilical Cord Blood transplantation? E. Gluckman WBMT meeting Cape Town November 14-16, 2014 The ideal HSCs source Immediate availability Few HLA restrictions
More informationNot All Stem Cells are the Same
Cord Blood Banking and Transplantation Jennifer Willert, M.D. Hematology/Oncology Blood and Marrow Transplant Rady Children s Hospital San Diego Clinical Professor UCSD Not All Stem Cells are the Same
More informationNarrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood
[Track 2: What Is a Transplant?] Narrator: Transplants using stem cells from the blood, bone marrow or umbilical cord blood can be an effective treatment for people with blood cancers such as leukemia,
More informationThe future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings. Prof. Tony Pagliuca
The future of unrelated Stem Cell Transplant in the UK: DOH Working Party Findings Prof. Tony Pagliuca UK STEM CELL STRATEGIC FORUM The future of unrelated donor SCT in the UK Antonio Pagliuca, Transplant
More informationInternational NetCord Foundation Executive Committee Conference Call Minutes May 21, 2014
International NetCord Foundation Executive Committee Conference Call Minutes May 21, 2014 Committee Members: Staff: President Etienne Baudoux and Drs. Gesine Koegler, Joanne Kurtzberg, Alexander Platz
More informationUnrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Craig Sauter and Juliet N.
Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignancies Craig Sauter and Juliet N. Barker Adult Allogeneic Bone Marrow Transplantation Service, Memorial Sloan-Kettering
More informationFriday, September 11, 2015
ADVISORY COUNCIL ON BLOOD STEM CELL TRANSPLANTATION (ACBSCT) U.S. Department of Health and Human Services NIH Fishers Lane Conference Center Rockville, MD 20852 Welcome and Opening Remarks Jeffrey McCullough,
More informationCord Blood Bank Business Plan
Cord Blood Bank Business Plan A sample of how to create a new program Produced by the AABB subsection: Cellular Therapy Business Management with major contributions by Nicole Omer TABLE OF CONTENTS Page
More informationSTEM CELL THERAPEUTIC OUTCOMES DATABASE
C W Bill Young Cell Transplantation Program STEM CELL THERAPEUTIC OUTCOMES DATABASE BUS06_1ppt Stem Cell Therapeutic and Research Act of 2005 (PL 109-129) 129) Authorizing law, preceded by efforts to:
More informationUMBILICAL CORD BLOOD HARVESTING & STORAGE
Protocol: TRP009 Effective Date: October 14, 2013 UMBILICAL CORD BLOOD HARVESTING & STORAGE Table of Contents Page COMMERCIAL, MEDICARE & MEDICAID COVERAGE RATIONALE... 1 BACKGROUND... 2 CLINICAL EVIDENCE...
More informationDEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT
www.narayanahealth.org DEPARTMENT OF BONE MARROW AND STEM CELL TRANSPLANT About Narayana Health City Narayana Health, one of India's largest and the world's most economical healthcare service providers
More informationGuidance for Industry and FDA Staff
Guidance for Industry and FDA Staff Investigational New Drug Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution
More informationUmbilical cord blood transplantation: a maturing technology
HEMATOPOIETIC STEM CELL TRANSPLANTATION I: EXPLOITING ALTERNATIVE DONORS Umbilical cord blood transplantation: a maturing technology Betul Oran 1 and Elizabeth Shpall 1 1 Department of Stem Cell Transplantation
More informationIn a number of genetic, hematologic, and oncologic
AMERICAN ACADEMY OF PEDIATRICS Cord Blood Banking for Potential Future Transplantation: Subject Review ABSTRACT. In recent years, umbilical cord blood, which contains a large number of hematopoietic stem
More informationPublic Cord Blood Banking at the National Cord Blood Program (NCBP)
Public Cord Blood Banking at the National Cord Blood Program (NCBP) A. Scaradavou, MD Medical Director, National Cord Blood Program, New York Blood Center Associate Attending, Pediatric BMT Memorial Sloan-Kettering
More informationTransmedcon 2014. Ahmedabad, Gujarat November 14-16, 2014
FACT Accreditation for Cord Blood Banks and Cellular Therapy Nadim Mahmud, MD, PhD Associate Professor of Medicine Division of Hematology/Oncology Director, Hospital Stem Cell Laboratory Blood & Marrow
More informationSummary of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Status
of Advisory Council on Blood Stem Cell Transplantation: Recommendations and Shelley Grant Branch Chief, Blood Stem Cell Transplantation Program September 11, 2015 Overview December 20, 2005 - HRSA began
More informationOUR JOURNEY THROUGH THE YEARS
The King Faisal Specialist Hospital and Research Centre Experience in Hematology, Oncology and Bone Marrow Transplantation OUR JOURNEY THROUGH THE YEARS REGGIE BELKHEDIM A Brief Overview: King Faisal Specialist
More informationHouse Resolution No. 37
california legislature regular session House Resolution No. Introduced by Assembly Member Hill August, House Resolution No. Relative to umbilical cord blood banking. WHEREAS, Since the first umbilical
More informationUmbilical Cord Blood (UCB) Transplantation: An Alternative to the Use of Unrelated Volunteer Donors?
Umbilical Cord Blood (UCB) Transplantation: An Alternative to the Use of Unrelated Volunteer Donors? Juliet N. Barker Memorial Sloan-Kettering Cancer Center, New York, NY Cryopreserved umbilical cord blood
More informationA fact sheet UNRELATED BONE MARROW AND CORD BLOOD STEM CELL TRANSPLANTS
A fact sheet UNRELATED BONE MARROW AND CORD BLOOD STEM CELL TRANSPLANTS Each year, thousands of patients are diagnosed with diseases treatable by a blood stem cell transplant. These blood stem cells can
More informationINFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002
INFORMATION ON STEM CELLS/BONE MARROW AND REINFUSION/TRANSPLANTATION SUR703.002 COVERAGE: SPECIAL COMMENT ON POLICY REVIEW: Due to the complexity of the Peripheral and Bone Marrow Stem Cell Transplantation
More informationFiscal Year 2013 Annual Progress Report on the C.W. Bill Young Cell Transplantation Program and National Cord Blood Inventory Program
U.S. Department of Health and Human Services Fiscal Year 2013 Annual Progress Report on the C.W. Bill Young Cell Transplantation Program and National Cord Blood Inventory Program Executive Summary The
More informationFACT WORKSHOP CORD BLOOD, CELLULAR THERAPY, REGENERATIVE MEDICINE INSPECTION AND ACCREDITATION WORKSHOP
FACT WORKSHOP CORD BLOOD, CELLULAR THERAPY, REGENERATIVE MEDICINE INSPECTION AND ACCREDITATION WORKSHOP WEDNESDAY 01/07/2015 Morning Parallel Sessions Cord Blood Banking Cellular Therapy/Regenerative Medicine
More informationUmbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation
Umbilical Cord Blood: An Alternative Allogeneic Stem Cell Source for Transplantation Mary J. Laughlin, MD Associate Professor of Medicine and Pathology Dr. Donald and Ruth Weber Goodman Professor of Innovative
More informationStem Cell Background Paper
Stem Cell Background Paper Introduction...2 Stem Cell Basics...3 Stem Cell Process Flow...9 Comparison of Blood, Stem Cells, Tissues and Organs Processes...10 Responsibilities for the Blood, Stem Cells,
More informationInformed Consent in Umbilical Cord Blood Collection, Storage and Donation: A Bloody Mess
Informed Consent in Umbilical Cord Blood Collection, Storage and Donation: A Bloody Mess Susan P. Raine, J.D., M.D., L.L.M. Candidate Over the past decade, umbilical cord blood has gone from being discarded
More informationcord blood saves lives...
cord blood saves lives... ...by providing a rich source of blood stem cells that can be used to treat over 80 different diseases including leukemia, lymphoma, thalassemia, Tay-Sachs and sickle cell anemia.
More informationSaving Your Baby s Cord Blood
Saving Your Baby s Cord Blood An Important Pregnancy Decision 1-888-CORD BLOOD HEALTHY FUTURES ARE Born at CBR For every parent who wishes they could do more to protect their family s health, there s Cord
More informationBLOOD AND MARROW TRANSPLANT PROGRAM
BLOOD AND MARROW TRANSPLANT PROGRAM We offer a team approach to patient care that centers around our patients and their caregivers; we focus on providing comprehensive, holistic care for the best possible
More informationCellular Therapy and Cord Blood Market Report 2013 Page 1. Kathy Gray Worldwide Market Reports & Consulting Coordinator Select Biosciences
Cellular Therapy and Cord Blood Market Report 2013 Kathy Gray Worldwide Market Reports & Consulting Coordinator Select Biosciences k.gray@selectbio.com Select Biosciences Market Reports Website: SelectBiosciences.com/marketreports/
More informationEconomics of Cord Blood Banking. Michael Boo NMDP Be The Match September 11, 2015
Economics of Cord Blood Banking Michael Boo NMDP Be The Match September 11, 2015 Historical Use UCB Use Data 2 NMDP Historical Transplants by Product 7,000 6,500 6,000 5,500 5,000 4,500 4,000 3,500 3,000
More informationCord Blood Biology and Transplantation
Cord Blood Biology and Transplantation Yossi Cohen MD MSc and Arnon Nagler MD Institute of Hematology, Department of Bone Marrow Transplantation and Cord Blood Bank, Sheba Medical Center, Tel Hashomer,
More information